Literature DB >> 12664255

[In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity].

L Petrovic1, K A Schlegel, J Ries, J Park, E Diebel, S Schultze-Mosgau, J Wiltfang.   

Abstract

Taurolidine (Taurolin) is a derivative of the amino acid taurine, successfully used in the treatment of peritonitis. In vitro and in vivo studies have shown that taurolidine inhibits cell proliferation and induces apoptosis in a variety of tumor cell lines. At present there are no published studies on the use of taurolidine in the treatment of squamous cell carcinoma. Our aim was to examine the inhibition of cell proliferation and induction of apoptosis in cell lines SCC 4 and SCC 15 treated with taurolidine in concentrations of 0.01%, 0.1%, and 0.5%. Analogue to the present investigations on adenocarcinoma cell lines, we used toxic antiseptic povidone iodine in the same concentration as for the reference group. Untreated cells were used as a control group. The cells were incubated with taurolidine or povidone iodine once for 2 h at 37 degrees C in 5% CO(2). Cell proliferation was assessed using WST-1 labeling kit after 3, 24, 48, 72, and 96 h. The additional measurement of cell apoptosis was examined using ELISA(PLUS) cell death detection kit and performed after 0, 24, and 48 h. The findings showed a significant inhibition of cell proliferation and induction of apoptosis in taurolidine-treated cells SCC 4 and SCC 15 in contrast to the reference group treated with povidone iodine or the untreated control group.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12664255     DOI: 10.1007/s10006-003-0452-5

Source DB:  PubMed          Journal:  Mund Kiefer Gesichtschir        ISSN: 1432-9417


  27 in total

1.  The effects of three non-antibiotic, antimicrobial agents on the surface hydrophobicity of certain micro-organisms evaluated by different methods.

Authors:  D S Jones; S P Gorman; D F McCafferty; A D Woolfson
Journal:  J Appl Bacteriol       Date:  1991-09

2.  The in vitro and in vivo activity of taurolin against anaerobic pathogenic organisms.

Authors:  M K Browne; G B Leslie; R W Pfirrman; H Brodhage
Journal:  Surg Gynecol Obstet       Date:  1977-12

Review 3.  Tumor angiogenesis: past, present and the near future.

Authors:  R S Kerbel
Journal:  Carcinogenesis       Date:  2000-03       Impact factor: 4.944

4.  Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.

Authors:  P Calabresi; F A Goulette; J W Darnowski
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

5.  New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat.

Authors:  C A Jacobi; F J Peter; F A Wenger; J Ordemann; J M Müller
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

6.  Effects of taurolidine and octreotide on port site and liver metastasis after laparoscopy in an animal model of pancreatic cancer.

Authors:  F A Wenger; M Kilian; C Braumann; A Neumann; J Ridders; F J Peter; H Guski; C A Jacobi
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

7.  Taurolidine inhibits tumor cell growth in vitro and in vivo.

Authors:  M McCourt; J H Wang; S Sookhai; H P Redmond
Journal:  Ann Surg Oncol       Date:  2000-10       Impact factor: 5.344

8.  Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells.

Authors:  G L Clayman; D L Taylor; F J Liu; P Lavedan; H E Savage; S P Schantz
Journal:  Laryngoscope       Date:  1993-03       Impact factor: 3.325

9.  Treatment failure and margin status in head and neck cancer. A critical view on the potential value of molecular pathology.

Authors:  Pieter J Slootweg; Gert Jan Hordijk; Yolanda Schade; Robert J J van Es; Ronald Koole
Journal:  Oral Oncol       Date:  2002-07       Impact factor: 5.337

10.  An immunological outcome predictive score for head and neck carcinoma patients.

Authors:  W Kaffenberger; L Hölzer-Müller; T Auberger; B P Clasen; G Hohlmeier; D van Beuningen
Journal:  Strahlenther Onkol       Date:  1995-08       Impact factor: 3.621

View more
  6 in total

1.  The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.

Authors:  Kevin Marley; Stuart C Helfand; Wade A Edris; John E Mata; Alix I Gitelman; Jan Medlock; Bernard Séguin
Journal:  BMC Vet Res       Date:  2013-01-18       Impact factor: 2.741

2.  Evaluation of the safety and efficacy of TRAIL and taurolidine use on human fibrosarcoma xenografts in vivo.

Authors:  Kamran Harati; Sabine Emmelmann; Björn Behr; Ole Goertz; Tobias Hirsch; Nicolai Kapalschinski; Jonas Kolbenschlag; Ingo Stricker; Andrea Tannapfel; Marcus Lehnhardt; Adrien Daigeler
Journal:  Oncol Lett       Date:  2016-01-15       Impact factor: 2.967

3.  The potential health benefits of taurine in cardiovascular disease.

Authors:  Yan-Jun Xu; Amarjit S Arneja; Paramjit S Tappia; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2008

4.  Novel protective role of curcumin and taurine combination against experimental hepatocarcinogenesis.

Authors:  Motawa Eisa El-Houseini; Ibrahim Ali El-Agoza; Mona Mohamed Sakr; Ghada Mohamed El-Malky
Journal:  Exp Ther Med       Date:  2016-12-02       Impact factor: 2.447

5.  Pharmacokinetic study and evaluation of the safety of taurolidine for dogs with osteosarcoma.

Authors:  Kevin Marley; Stuart C Helfand; Jennifer Simpson; John E Mata; William G Tracewell; Lisa Brownlee; Shay Bracha; Bernard Séguin
Journal:  J Exp Clin Cancer Res       Date:  2013-10-11

6.  Taurine Augments Telomerase Activity and Promotes Chondrogenesis in Dental Pulp Stem Cells.

Authors:  Mohammed Mashyakhy; Ahmed Alkahtani; Abdulaziz S Abumelha; Reham Jamal Sharroufna; Mazen F Alkahtany; Mohamed Jamal; Ali Robaian; Sultan Binalrimal; Hitesh Chohan; Vikrant R Patil; A Thirumal Raj; Shilpa Bhandi; Rodolfo Reda; Luca Testarelli; Shankargouda Patil
Journal:  J Pers Med       Date:  2021-05-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.